Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by HF Advisory Group LLC

HF Advisory Group LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,176 shares of the biopharmaceutical company’s stock after selling 1,737 shares during the period. HF Advisory Group LLC’s holdings in Gilead Sciences were worth $1,494,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA grew its position in shares of Gilead Sciences by 0.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock valued at $5,887,000 after buying an additional 522 shares during the last quarter. Seven Eight Capital LP acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $525,000. MQS Management LLC grew its position in shares of Gilead Sciences by 33.9% during the second quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 1,157 shares during the last quarter. Ieq Capital LLC increased its holdings in shares of Gilead Sciences by 3.7% in the 2nd quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company’s stock valued at $4,749,000 after acquiring an additional 2,453 shares during the period. Finally, Canada Pension Plan Investment Board raised its position in Gilead Sciences by 91.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 2,699,863 shares of the biopharmaceutical company’s stock valued at $185,238,000 after purchasing an additional 1,289,420 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Robert W. Baird lifted their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Stock Up 0.2 %

GILD opened at $91.84 on Friday. The company has a market cap of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The business’s fifty day moving average is $91.75 and its two-hundred day moving average is $83.97. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock worth $42,130,461. 0.29% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.